Press Releases
Media
Publications

October 25, 2022

Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity

Science Immunology 7: 76
Simone A. Minnie, Olivia G. Waltner, Kathleen S. Ensbey, Nicole S. Nemychenkov, Christine R. Schmidt, Shruti S. Bhise, Samuel R. W. Legg, Gabriela Campoy, Luke D. Samson, Rachel D. Kuns, Ting Zhou, John D. Huck, Slavica Vuckovic2 Danniel Zamora, Albert Yeh, Andrew Spencer, Motoko Koyama, Kate A. Markey, Steven W. Lane, Michael Boeckh, Aaron M. Ring, Scott N. Furlan, Geoffrey R. Hill

June 24, 2020

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

Nature 583, 609–614
Ting Zhou, William Damsky, Orr-El Weizman, Meaghan K. McGeary, K. Patricia Hartmann, Connor E. Rosen, Suzanne Fischer, Ruaidhri Jackson, Richard A. Flavell, Jun Wang, Miguel F. Sanmamed, Marcus W. Bosenberg & Aaron M. Ring

April 5, 2023

Simcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors

August 16, 2022

Simcha Therapeutics Accelerates Growth with Key Leadership Appointments, Expanded Research and Option Agreement with Yale School of Medicine

January 27, 2022

Simcha Therapeutics Raises $40 Million Series B Financing and Initiates Phase 1/2 Study to Evaluate Novel Interleukin-18 Variant in Cancer

June 24, 2020

Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System

December 7, 2022

ASH22 could be IL-18’s watershed moment

January 27, 2022

Going after an old GSK target in a new way, a Yale spinout hits the clinic and nabs a modest raise

June 24, 2020

Engineering a better immunotherapy to outwit cancer — and launch a biotech

June 24, 2020

Simcha debuts with $25M to advance custom-built IL-18 for cancer